ArticleInternational ophthalmology2025
Risk factors for hyphema following pars plana vitrectomy with intravitreal gas injection in vitreoretinal disease.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the risk factors and outcomes associated with hyphema after pars plana vitrectomy (PPV) with intravitreal gas injection.
methodsA retrospective study was conducted on 252 patients (252 eyes) who underwent PPV with intravitreal gas injection between January 1, 2011, and August 30, 2023. Patients were grouped based on the presence of hyphema within one week postoperatively. We analyzed the clinical characteristics of the patients, surgical procedures, and the risk factors associated with the occurrence of hyphema.
resultsPostoperative hyphema developed in 16 (6.3%) eyes. The hyphema group was significantly younger (54.00 ± 10.88 years vs. 61.06 ± 12.41 years, P = 0.027) compared to the non-hyphema group. Additionally, the hyphema group had a higher percentage of high myopia (68.8% vs. 19.1%, P < 0.001) and a longer surgical duration (89.00 ± 33.35 min vs. 71.00 ± 28.64 min, P = 0.017) compared to the non-hyphema group. The anatomical success rate of the primary surgery at 6 months did not differ significantly between the hyphema and non-hyphema groups (93.8% vs. 95.3%, P = 0.773). High myopia (OR, 10.014; 95% CI 3.211-31.235; P < 0.001) and longer surgical duration (min) (OR, 1.019; 95% CI 1.003-1.035; P = 0.019) were significantly associated with the occurrence of hyphema.
conclusionHigh myopia and longer surgical duration were risk factors for hyphema development after PPV with intravitreal gas injection. Hyphema occurrence may not have had a significant impact on the anatomical success rate at 6 months.
Indexed as
Identifiers
40085169What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.